Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-550-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions
What is Evofem Biosciences' stock symbol?
Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."
How were Evofem Biosciences' earnings last quarter?
Evofem Biosciences Inc (NASDAQ:EVFM) issued its quarterly earnings data on Friday, March, 1st. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.15. View Evofem Biosciences' Earnings History.
When is Evofem Biosciences' next earnings date?
What price target have analysts set for EVFM?
5 brokerages have issued 12 month target prices for Evofem Biosciences' shares. Their predictions range from $8.00 to $15.00. On average, they expect Evofem Biosciences' share price to reach $10.70 in the next year. This suggests a possible upside of 194.8% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.
What is the consensus analysts' recommendation for Evofem Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.
What are Wall Street analysts saying about Evofem Biosciences stock?
Here are some recent quotes from research analysts about Evofem Biosciences stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate the Overweight rating and $9 PT for EVFM stock. We continue to believe Amphora, if successfully developed, could become an important new contraceptive modality for women electing not to use hormonal or device-related methods. The company is making progress on a long-term financing strategy to fund pre-commercial and, if approved, launch activities of Amphora that may involve potential sources of non-dilutive capital, which we believe may benefit shareholders." (3/4/2019)
- 2. According to Zacks Investment Research, "Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA. " (3/1/2019)
- 3. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-based approach, with a 15% discount rate and an effective tax rate of 30% applied to all future cash flows. Our probability of success for Amphora in contraception is 70%, which translates into a risk-adjusted net present value (rNPV) of $250M." (8/29/2018)
Has Evofem Biosciences been receiving favorable news coverage?
News headlines about EVFM stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evofem Biosciences earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the immediate future.
Who are some of Evofem Biosciences' key competitors?
Some companies that are related to Evofem Biosciences include Catalyst Pharmaceuticals (CPRX), OvaScience (OVAS), Theratechnologies (THERF), Concert Pharmaceuticals (CNCE), Progenics Pharmaceuticals (PGNX), XBiotech (XBIT), Beyondspring (BYSI), Aptorum Group (APM), Axsome Therapeutics (AXSM), Abeona Therapeutics (ABEO), ImmunoGen (IMGN), OptiNose (OPTN), Albireo Pharma (ALBO), Sinovac Biotech (SVA) and Kadmon (KDMN).
What other stocks do shareholders of Evofem Biosciences own?
Who are Evofem Biosciences' key executives?
Evofem Biosciences' management team includes the folowing people:
- Ms. Saundra Pelletier, CEO & Director
- Mr. Justin J. File, Chief Financial Officer
- Dr. Kelly Culwell, Chief Medical Officer
- Mr. Jason Abrams, Accounting Mang.
- Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)
Who are Evofem Biosciences' major shareholders?
Evofem Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.42%), Geode Capital Management LLC (0.28%) and Geode Capital Management LLC (0.28%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Institutional Ownership Trends for Evofem Biosciences.
Which major investors are selling Evofem Biosciences stock?
Which major investors are buying Evofem Biosciences stock?
EVFM stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Insider Buying and Selling for Evofem Biosciences.
How do I buy shares of Evofem Biosciences?
Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evofem Biosciences' stock price today?
One share of EVFM stock can currently be purchased for approximately $3.63.
How big of a company is Evofem Biosciences?
Evofem Biosciences has a market capitalization of $102.22 million. The biotechnology company earns $-125,710,000.00 in net income (profit) each year or ($5.74) on an earnings per share basis.
What is Evofem Biosciences' official website?
How can I contact Evofem Biosciences?
Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]
MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
